Related coverage linked through entity extraction aliases.
Jul 10, 2026
Australian and US regulators have warned about sexual enhancement and honey products containing undeclared prescription medicines, prompting recalls and safety alerts. UK regulators also caution about underreported drug-herb interactions and herb-induced liver injury.
May 03, 2026
A systematic review found strong FAERS signals linking labetalol to rare liver injury, while a case report describes hyperacute liver failure from high-dose atorvastatin that resolved after discontinuation.
Jun 13, 2026
The FDA approved pivekimab sunirine-pvzy (Decnupaz) for adults with BPDCN on May 27, 2026, based on CADENZA trial data showing a 69.7% CR/CRc rate in treatment-naïve patients.
Mar 10, 2026
The global 3D bioprinted human tissue market is projected to grow from $2.5 billion in 2025 to $3.9 billion by 2035 at a 4.6% CAGR, driven by regenerative medicine demand and advances in hybrid hydrogel materials for tissue engineering.
Feb 26, 2026
AstraZeneca's CALQUENCE received FDA approval as the first all-oral, fixed-duration regimen for chronic lymphocytic leukemia, while the EMA validated the marketing authorization application for ENHERTU in HER2-positive breast cancer treatment.
Feb 23, 2026
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
Feb 20, 2026
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.
Feb 16, 2026
Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.
